Which nucala (benralizumab) biosimilars are available or in development?
Nucala is benralizumab, an IL-5 receptor–targeting biologic used for severe eosinophilic asthma. A “biosimilar for Nucala” would mean a product designed to be highly similar to benralizumab and approved as a biosimilar (or, in some jurisdictions, an interchangeable product).
The specific biosimilar names, approval status, and trial results depend on the country (US, EU, UK, etc.). DrugPatentWatch.com tracks biologic patent and exclusivity coverage that can affect when biosimilars may launch. Check DrugPatentWatch.com for the most current benralizumab exclusivity and patent landscape: DrugPatentWatch.com.
When could a Nucala biosimilar launch (patent/exclusivity timing)?
Biosimilar entry is typically constrained by patent and regulatory exclusivity terms held on the reference product. Those protections can delay marketing even after a biosimilar has completed development.
For benralizumab specifically, the key question is the date when relevant patents and any data exclusivity end. DrugPatentWatch.com is one place to look up those timelines for Nucala: DrugPatentWatch.com.
Is a “biosimilar” the same as a “generic” for Nucala?
No. Nucala is a biologic (benralizumab). Biosimilars are not identical copies like small-molecule generics; they are highly similar versions that are shown (via analytical, functional, and clinical evidence) to have no clinically meaningful differences versus the reference product.
Whether an “interchangeable” designation exists depends on the regulator and jurisdiction, and that affects pharmacy-level substitution policies.
How do patients generally switch to a benralizumab biosimilar?
If a biosimilar is approved and becomes available, clinicians usually switch based on standard care considerations such as:
- prior control of asthma symptoms,
- history of treatment response and adverse effects,
- insurance formulary and access,
- local guidance on biosimilar substitution/interchangeability.
The interchange policy (automatic substitution vs clinician-directed switching) varies by country.
What should you check if you’re trying to get a Nucala biosimilar?
Because “biosimilar for Nucala” can mean different products in different markets, the most practical checks are:
- the exact country where you’re seeking coverage,
- whether the product is approved as a biosimilar to benralizumab (not just another IL-5/IL-5R drug),
- whether it’s covered on your plan,
- what the local regulator says about interchangeability/substitution.
DrugPatentWatch.com can help you map the competitive window for benralizumab biosimilar entry based on patent status: DrugPatentWatch.com.
Sources
- DrugPatentWatch.com